Explore

Rapid Read Rapid Read
Utah Medical Board Demands Suspension of AI Doctor Program Over Safety Concerns

Utah Medical Board Demands Suspension of AI Doctor Program Over Safety Concerns

The Utah Medical Licensing Board has called for the immediate suspension of a state-run artificial intelligence (AI) doctor program, citing safety concerns. The program, initiated by Utah’s Office of Artificial Intelligence Policy in collaboration with AI startup Doctronic, was designed to allow a chatbot to conduct clinical evaluations and autonomously renew prescriptions for nearly 200 drugs. The Medical Board expressed its concerns in a letter, stating that the program was launched without their consultation, potentially putting Utah citizens at risk. The board emphasized the need for further discussion before the program proceeds, highlighting the importance of oversight in medical practices involving AI technology.
Rapid Read Rapid Read
Early Adulthood Weight Gain Linked to Increased Mortality Risk

Early Adulthood Weight Gain Linked to Increased Mortality Risk

A study by Lund University researchers indicates that weight gain during early adulthood is strongly associated with a higher risk of premature death. The study tracked over 600,000 individuals and found that those who developed obesity between ages 17 and 29 were 70% more likely to die of any cause compared to those who gained weight later in life. The research suggests that the duration of obesity, rather than weight gain in later adulthood, is a key factor in mortality risk. The study highlights the importance of early intervention in preventing obesity.
Trendline Trendline
Cardiologist Debunks Myth: Sleeping on Left Side Not Harmful to Heart Health

Cardiologist Debunks Myth: Sleeping on Left Side Not Harmful to Heart Health

Cardiologist Debunks Myth: Sleeping on Left Side Not Harmful to Heart Health
Rapid Read Rapid Read
Paxlovid Fails to Reduce Hospitalization and Death in Vaccinated High-Risk COVID Patients, Study Finds

Paxlovid Fails to Reduce Hospitalization and Death in Vaccinated High-Risk COVID Patients, Study Finds

Recent trials conducted in the United Kingdom and Canada have revealed that the antiviral drug Paxlovid does not significantly reduce hospitalization or death rates among vaccinated high-risk COVID-19 patients. The trials, known as PANORAMIC and CanTreatCOVID, involved over 4,000 participants who were either 50 years or older or had underlying health conditions. Despite being vaccinated, these high-risk individuals did not experience a significant reduction in severe outcomes when treated with Paxlovid compared to those receiving usual care. The study, published in the New England Journal of Medicine, highlights that while Paxlovid may speed up recovery, its effectiveness in preventing severe illness in vaccinated individuals remains unclear.
Trendline Trendline
Cardiologist Recommends Heart-Healthy Food Swaps to Improve Diet

Cardiologist Recommends Heart-Healthy Food Swaps to Improve Diet

Cardiologist Recommends Heart-Healthy Food Swaps to Improve Diet
Trendline Trendline
Cardiologist Advises Against Late-Night Habits to Improve Heart Health

Cardiologist Advises Against Late-Night Habits to Improve Heart Health

Cardiologist Advises Against Late-Night Habits to Improve Heart Health
Trendline Trendline
Adial Pharmaceuticals Advances AD04 for Alcohol Use Disorder with Successful Manufacturing Step

Adial Pharmaceuticals Advances AD04 for Alcohol Use Disorder with Successful Manufacturing Step

Adial Pharmaceuticals Advances AD04 for Alcohol Use Disorder with Successful Manufacturing Step
Rapid Read Rapid Read
FDA Approves Merck's IDVYNSO for HIV Treatment

FDA Approves Merck's IDVYNSO for HIV Treatment

The U.S. Food and Drug Administration (FDA) has approved Merck's IDVYNSO, a once-daily, two-drug regimen for the treatment of HIV-1 in adults. IDVYNSO combines doravirine and islatravir and is designed for patients who are virologically suppressed with no history of treatment failure. This approval marks the first non-INSTI, tenofovir-free regimen to demonstrate non-inferior efficacy compared to a three-drug regimen in a Phase 3 trial. IDVYNSO will be available in pharmacies starting May 11, offering a new treatment option for people living with HIV.
Trendline Trendline
Consumer Reports Finds Issues with Fish Oil Supplements

Consumer Reports Finds Issues with Fish Oil Supplements

Consumer Reports Finds Issues with Fish Oil Supplements
Trendline Trendline
DemeRx Advances DMX-1001 for Alcohol Use Disorder with FDA Approval

DemeRx Advances DMX-1001 for Alcohol Use Disorder with FDA Approval

DemeRx Advances DMX-1001 for Alcohol Use Disorder with FDA Approval
Rapid Read Rapid Read
FDA Issues Warning to New Life Pharma Over Manufacturing Violations

FDA Issues Warning to New Life Pharma Over Manufacturing Violations

The FDA has issued a warning letter to New Life Pharma following an inspection of their New Jersey facility, which revealed significant compliance issues with current good manufacturing practices (CGMP). The inspection, conducted in February, found that New Life was manufacturing GLP-1 drug products, including semaglutide and tirzepatide vials, without adequate procedures to prevent microbiological contamination. The FDA's warning letter highlights that New Life denied inspectors access to certain areas of the facility, which is a violation of inspection protocols. The company has been given 15 working days to respond to the FDA's concerns. New Life had previously recalled semaglutide and tirzepatide vials in February due to these compliance issues.
Rapid Read Rapid Read
CDC Warns of Increased Lyme Disease Risk as Tick Population Rises

CDC Warns of Increased Lyme Disease Risk as Tick Population Rises

The Centers for Disease Control and Prevention (CDC) has reported an expected rise in Lyme disease cases in 2026, correlating with an increase in tick populations. This year has already seen the highest number of emergency room visits for tick bites in over a decade. The CDC's warning highlights the need for public awareness and preventive measures to protect against tick-borne illnesses. The rise in tick populations is attributed to favorable environmental conditions, which have allowed ticks to thrive and expand their habitats.